Baxter Spins Off Drug Business To Focus On Devices, Anesthesia & Nutrition Products
This article was originally published in The Gray Sheet
Executive Summary
Kidney dialysis and biosurgery will be two major focus points for a newly refined Baxter after it spins off its biopharmaceuticals business, as planned for mid-2015.